CMAJ • February 15, 2005; 172 (4). doi:10.1503/cmaj.1031785.
© 2005 Canadian Medical Association or its licensors
All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.
This Article
Right arrow Abstract
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lampinen, T. M.
Right arrow Articles by Hogg, R. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lampinen, T. M.
Right arrow Articles by Hogg, R. S.
Related Collections
Right arrow Drugs: immunological products and vaccines
Right arrow HIV infection, AIDS

Sexual risk behaviour of Canadian participants in the first efficacy trial of a preventive HIV-1 vaccine

Thomas M. Lampinen, Keith Chan, Robert S. Remis, Maraki Fikre Merid, Melanie Rusch, Jean Vincelette, Ken Logue, Vladimir Popovic, Michel Alary, Martin T. Schechter and Robert S. Hogg

From the British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC (Lampinen, Chan, Rusch, Schechter, Hogg); the Department of Health Care and Epidemiology, University of British Columbia, Vancouver, BC (Lampinen, Rusch, Schechter, Hogg); the Department of Public Health Science, University of Toronto, Toronto, Ont. (Remis, Merid); Hôpital Saint-Luc du Centre hospitalier de l'Université de Montréal (CHUM), Montréal, Que. (Vincelette); University Health Network, Toronto General Hospital, Toronto, Ont. (Logue); Vaxgen Inc., Brisbane, Calif. (Popovic); and the Population Health Research Unit, Centre hospitalier affilié universitaire de Québec and Université Laval, Québec, Que. (Alary). Robert Remis is coordinator of CANVAC Project 1.5 (Behavioural and Epidemiological Aspects of HIV Vaccine Trials), and Robert Remis, Jean Vincelette and Michel Alary are coinvestigators with the project.


View this table:

[in a new window]
  		Table 1.

 

View this table:

[in a new window]
  		Table 2.

 

View this table:

[in a new window]
  		Table 3.

 

View this table:

[in a new window]
  		Table 4.